[go: up one dir, main page]
IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v28y2010i7p539-553.html
   My bibliography  Save this article

The State of Health Economic Evaluation Research in Nigeria

Author

Listed:
  • Paul Gavaza
  • Karen Rascati
  • Abiola Oladapo
  • Star Khoza
Abstract
This study assessed the state of health economic evaluation (including pharmacoeconomic) research in Nigeria. A literature search was conducted to identify health economic articles pertaining to Nigeria. Two reviewers independently scored each article in the final sample using a data collection form designed for the study. A total of 44 studies investigating a wide variety of diseases were included in the review. These articles were published in 34 different journals, mostly based outside of Nigeria, between 1988 and 2009. On average, each article was written by four authors. Most first authors had medical/clinical affiliations and resided in Nigeria at the time of publication of the study. Based on a 1 to 10 scale, with 10 indicating the highest quality, the mean quality score for all studies was 7.29 (SD 1.21) and 59% of the articles were of fair quality (score 5–7); 5% were of even lower quality. The quality of articles was statistically significantly (p 0.05) related to the country of residence of the primary author (non-Nigeria=higher), country of the journal (non-Nigeria=higher), primary objective of the study (economic analysis=higher) and type of economic analysis conducted (economic evaluations higher than cost studies). The conduct of health economic (including pharmacoeconomic) research in Nigeria was limited and about two-thirds of published articles were of suboptimal quality. More and better quality health economic research in Nigeria is warranted. Copyright Adis Data Information BV 2010

Suggested Citation

  • Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2010. "The State of Health Economic Evaluation Research in Nigeria," PharmacoEconomics, Springer, vol. 28(7), pages 539-553, July.
    • Handle: RePEc:spr:pharme:v:28:y:2010:i:7:p:539-553
    DOI: 10.2165/11536170-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11536170-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11536170-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Gerard, Karen, 1992. "Cost-utility in practice: A policy maker's guide to the state of the art," Health Policy, Elsevier, vol. 21(3), pages 249-279, July.
    2. Onwujekwe, Obinna & Dike, Nkem & Chukwuka, Chinwe & Uzochukwu, Benjamin & Onyedum, Cajetan & Onoka, Chima & Ichoku, Hyacinth, 2009. "Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria," Health Policy, Elsevier, vol. 90(2-3), pages 223-229, May.
    3. Annemarie Wouters, 1993. "The cost and efficiency of public and private health care facilities in Ogun state, Nigeria," Health Economics, John Wiley & Sons, Ltd., vol. 2(1), pages 31-42, April.
    4. Fatiregun, Akinola Ayoola & Osungbade, Kayode O. & Olumide, Aderonke E., 2009. "Cost-effectiveness of screening methods for urinary schistosomiasis in a school-based control programme in Ibadan, Nigeria," Health Policy, Elsevier, vol. 89(1), pages 72-77, January.
    5. Onwujekwe, Obinna & Chima, Reginald & Shu, Elvis & Okonkwo, Paul, 2002. "Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences," Health Policy, Elsevier, vol. 62(1), pages 31-51, October.
    6. Yot Teerawattananon & Steve Russell & Miranda Mugford, 2007. "A Systematic Review of Economic Evaluation Literature in Thailand," PharmacoEconomics, Springer, vol. 25(6), pages 467-479, June.
    7. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453.
    8. Damian Walker & Julia A. Fox‐Rushby, 2000. "Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature," Health Economics, John Wiley & Sons, Ltd., vol. 9(8), pages 681-698, December.
    9. Eyitayo Lambo, 1983. "An Optimization-Simulation Model of a Rural Health Center in Nigeria," Interfaces, INFORMS, vol. 13(3), pages 29-35, June.
    10. David Canning & Ajay Mahal & Kunle Odumosu & Prosper OkonkwoZhiwei, 2006. "Assessing the Economic Impact of HIV/AIDS on Nigerian Households: A Propensity Score Matching Approach," PGDA Working Papers 1606, Program on the Global Demography of Aging.
    11. Onwujekwe, Obinna & Chima, Reginald & Okonkwo, Paul, 2000. "Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endemic Nigerian communities," Health Policy, Elsevier, vol. 54(2), pages 143-159, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    2. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.
    3. Pooja Desai & Hitesh Chandwani & Karen Rascati, 2012. "Assessing the Quality of Pharmacoeconomic Studies in India," PharmacoEconomics, Springer, vol. 30(9), pages 749-762, September.
    4. Bach Xuan Tran & Vuong Minh Nong & Rachel Marie Maher & Phuong Khanh Nguyen & Hoat Ngoc Luu, 2014. "A Systematic Review of Scope and Quality of Health Economic Evaluation Studies in Vietnam," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-12, August.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Benjarin Santatiwongchai & Varit Chantarastapornchit & Thomas Wilkinson & Kittiphong Thiboonboon & Waranya Rattanavipapong & Damian G Walker & Kalipso Chalkidou & Yot Teerawattananon, 2015. "Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-15, May.
    2. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.
    3. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    4. Maria-Florencia Hutter & Roberto Rodríguez-Ibeas & Fernando Antonanzas, 2014. "Methodological reviews of economic evaluations in health care: what do they target?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 829-840, November.
    5. Kittiphong Thiboonboon & Benjarin Santatiwongchai & Varit Chantarastapornchit & Waranya Rattanavipapong & Yot Teerawattananon, 2016. "A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 659-672, December.
    6. Krol, Marieke & Brouwer, Werner, 2015. "Unpaid work in health economic evaluations," Social Science & Medicine, Elsevier, vol. 144(C), pages 127-137.
    7. Paal Joranger & Arild Nesbakken & Halfdan Sorbye & Geir Hoff & Arne Oshaug & Eline Aas, 2020. "Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 321-334, April.
    8. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    9. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    10. Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal, 2018. "Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events," PharmacoEconomics - Open, Springer, vol. 2(4), pages 371-380, December.
    11. Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel, 2012. "Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands," PharmacoEconomics, Springer, vol. 30(3), pages 219-227, March.
    12. Ijeoma Nkem Okedo‐Alex & Ifeyinwa Chizoba Akamike & Obumneme Benaiah Ezeanosike & Chigozie Jesse Uneke, 2019. "A review of the incidence and determinants of catastrophic health expenditure in Nigeria: Implications for universal health coverage," International Journal of Health Planning and Management, Wiley Blackwell, vol. 34(4), pages 1387-1404, October.
    13. Khan, Md. Tajuddin & Kishore, Avinash & Joshi, Pramod Kumar, 2016. "Gender dimensions on farmers’ preferences for direct-seeded rice with drum seeder in India:," IFPRI discussion papers 1550, International Food Policy Research Institute (IFPRI).
    14. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    15. Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer, 2017. "Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model," PharmacoEconomics - Open, Springer, vol. 1(1), pages 37-51, March.
    16. Christopher Fitzpatrick & Katherine Floyd, 2012. "A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis," PharmacoEconomics, Springer, vol. 30(1), pages 63-80, January.
    17. Hareth Al-Janabi & Terry N. Flynn & Joanna Coast, 2011. "Estimation of a Preference-Based Carer Experience Scale," Medical Decision Making, , vol. 31(3), pages 458-468, May.
    18. Round, Jeff, 2012. "Is a QALY still a QALY at the end of life?," Journal of Health Economics, Elsevier, vol. 31(3), pages 521-527.
    19. Rossi, Pauline & Villar, Paola, 2020. "Private health investments under competing risks: Evidence from malaria control in Senegal," Journal of Health Economics, Elsevier, vol. 73(C).
    20. Ching-Yun Wei & Ruben G. W. Quek & Guillermo Villa & Shravanthi R. Gandra & Carol A. Forbes & Steve Ryder & Nigel Armstrong & Sohan Deshpande & Steven Duffy & Jos Kleijnen & Peter Lindgren, 2017. "A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 35(3), pages 297-318, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:28:y:2010:i:7:p:539-553. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.